Back

Elucidating the Impact of Hypericum alpestre Extract and L-NAME on the PI3K/Akt Signaling Pathway in A549 Lung Adenocarcinoma Cells

Javrushyan, H.; Ginovyan, M.; Petrosyan, G.; Qocharyan, M.; Harutyunyan, T.; Gevorgyan, S.; Karabekian, Z.; Maloyan, A.; Avtandilyan, N.

2024-05-04 cancer biology
10.1101/2024.05.02.592167 bioRxiv
Show abstract

Plants within the Hypericaceae family have been traditionally used for their medicinal properties, showcasing a wide range of effects such as antibacterial, antiviral, and antioxidant qualities. Hypericum alpestre (HA) extracts have exhibited significant cytotoxicity against various cancer cell lines. The phenolic compounds found in HA extracts have attracted attention for their potential in cancer prevention. L-NAME, known for its ability to inhibit nitric oxide synthase (NOS) activity, has emerged as a promising approach in cancer therapy. However, the precise molecular mechanisms underlying the anticancer effects of HA and L-NAME remain unclear. This study aims to clarify the impact of HA and L-NAME on the PI3K/Akt signaling pathway in A549 lung adenocarcinoma cells, with a specific focus on TNFa/COX-2 and VEGFa/MMP-2 pathways. In silico analysis, they identified the compounds with the highest affinity for PI3K/Akt, a finding validated by subsequent in vitro experiments. Furthermore, the combination of herbs and L-NAME exhibited superior efficacy compared to the herb and 5-FU combination, as evidenced by the promotion of apoptosis. Both the herb alone and the combination of the herb with L-NAME demonstrated inhibitory effects on the TNFa/COX-2 and VEGFa/MMP-2 pathways. This therapeutic approach is hypothesized to operate through the PI3k/Akt cell signaling pathway. A better understanding of the interaction between HA polyphenols and PI3K/Akt signaling could pave the way for novel therapeutic strategies against cancer, including drug-resistant tumors.

Matching journals

The top 4 journals account for 50% of the predicted probability mass.

1
PLOS ONE
5266 papers in training set
Top 5%
27.3%
2
Molecules
39 papers in training set
Top 0.1%
12.2%
3
Pharmaceuticals
34 papers in training set
Top 0.1%
6.9%
4
Scientific Reports
3612 papers in training set
Top 14%
5.7%
50% of probability mass above
5
International Journal of Molecular Sciences
494 papers in training set
Top 1%
5.3%
6
Life Sciences
27 papers in training set
Top 0.1%
3.5%
7
Heliyon
152 papers in training set
Top 1%
3.3%
8
Biochemical Pharmacology
20 papers in training set
Top 0.1%
3.3%
9
Frontiers in Pharmacology
111 papers in training set
Top 1.0%
2.5%
10
Biomedicine & Pharmacotherapy
42 papers in training set
Top 0.4%
2.2%
11
Frontiers in Oncology
103 papers in training set
Top 2%
2.0%
12
Biochemistry and Biophysics Reports
30 papers in training set
Top 0.4%
1.8%
13
Cancers
213 papers in training set
Top 4%
1.2%
14
RSC Advances
22 papers in training set
Top 0.5%
1.2%
15
European Journal of Pharmacology
15 papers in training set
Top 0.3%
1.2%
16
Biomolecules
100 papers in training set
Top 2%
1.2%
17
ACS Omega
105 papers in training set
Top 3%
1.1%
18
Molecular Biology Reports
21 papers in training set
Top 0.7%
1.1%
19
Journal of Biomolecular Structure and Dynamics
43 papers in training set
Top 1.0%
0.9%
20
Cells
249 papers in training set
Top 8%
0.6%
21
International Journal of Biological Macromolecules
76 papers in training set
Top 2%
0.6%
22
eLife
5828 papers in training set
Top 67%
0.6%
23
PeerJ
308 papers in training set
Top 12%
0.6%